REGN - Regeneron Pharmaceuticals

-

$undefined

N/A

(N/A)

Regeneron Pharmaceuticals NasdaqGS:REGN Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Location: 777 Old Saw Mill River Road, Tarrytown, NY, 10591-6707, United States | Website: https://www.regeneron.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

57.15B

Cash

8.349B

Avg Qtr Burn

N/A

Short % of Float

2.84%

Insider Ownership

1.90%

Institutional Own.

92.13%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Evkeeza (evinacumab) Details
Homozygous familial hypercholesterolemia

Approved

Update

EYLEA (aflibercept) Details
Diabetic retinopathy

Approved

Quarterly sales

Praluent® (alirocumab) Details
Heterozygous familial hypercholesterolemia

Approved

Quarterly sales

Dupixent Details
Chronic obstructive pulmonary disease

Approved

Quarterly sales

Libtayo® (cemiplimab) Details
Non-small cell lung carcinoma, Cutaneous squamous cell carcinoma

Approved

Quarterly sales

Kevzara (sarilumab) Details
Polymyalgia rheumatica

Approved

Quarterly sales

Veopoz™ (pozelimab-bbfg) Details
Rare diseases, CD55-deficient protein-losing enteropathy , CHAPLE disease

Approved

Quarterly sales

Approved

Quarterly sales

Dupixent® (dupilumab) (IL-4 IL-13) Details
Chronic rhinosinusitis with nasal polyps

Approved

Quarterly sales

Approved

Quarterly sales

Kevzara (sarilumab) Details
Polyarticular juvenile idiopathic arthritis

Approved

Quarterly sales

EYLEA (aflibercept) Details
Retinopathy of prematurity

Approved

Quarterly sales

EYLEA HD (aflibercept) Details
Wet age-related macular degeneration , Diabetic macular edema

Approved

Quarterly sales

EYLEA HD® (aflibercept) Injection Details
Macular edema following retinal vein occlusion

PDUFA

Approval decision

Odronextamab Details
Follicular lymphoma, Diffuse large B cell lymphoma

PDUFA

Approval decision

Linvoseltamab (BCMAXCD3) Details
Blood cancer, Cancer, Multiple myeloma

PDUFA

Approval decision

PDUFA

Approval decision

Libtayo® (cemiplimab) Details
Cutaneous squamous cell carcinoma

BLA

Submission

Dupixent (dupilumab) Details
Skin disease/disorder, Atopic dermatitis

Phase 3

Data readout

Itepekimab Details
Chronic obstructive pulmonary disease

Phase 3

Data readout

Phase 3

Initiation

Fianlimab + Libtayo® (cemiplimab) Details
Advanced malignancies, Melanoma

Phase 2/3

Data readout

Fianlimab + Libtayo® (cemiplimab) Details
Non-small cell lung carcinoma

Phase 2/3

Data readout

Phase 1/2

Data readout

Phase 1

Data readout

Dupixent Details
Chronic inducible urticaria

Failed

Discontinued